APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Chemotherapy-induced Nausea and Vomiting Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Chemotherapy-induced Nausea and Vomiting Drugs Market Outlook and Growth Opportunities 2026

Report ID 173976980422 December 2025198 pages

Choose your research edition.

Industry ResearchChemotherapy-induced Nausea and Vomiting Drugs Industry Research Report 2026126 pages · $2,950 USDIndustry Growth & TrendsGlobal Chemotherapy-induced Nausea and Vomiting Drugs Industry Growth and Trends Forecast to 2032108 pages · $3,450 USDMarket StructureGlobal Chemotherapy-induced Nausea and Vomiting Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Chemotherapy-induced Nausea and Vomiting Drugs Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Chemotherapy-induced Nausea and Vomiting Drugs Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Chemotherapy-induced Nausea and Vomiting Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Chemotherapy-induced Nausea and Vomiting Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Chemotherapy-induced Nausea and Vomiting Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Chemotherapy-induced Nausea and Vomiting Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Chemotherapy-induced Nausea and Vomiting Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Chemotherapy-induced Nausea and Vomiting Drugs market include Eisai, Teva, Novartis, Merck, Mylan, Roche, Tesaro, Qilu Pharma and Mundipharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Chemotherapy-induced Nausea and Vomiting Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Chemotherapy-induced Nausea and Vomiting Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Chemotherapy-induced Nausea and Vomiting Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Chemotherapy-induced Nausea and Vomiting Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Chemotherapy-induced Nausea and Vomiting Drugs Segment by Company

Eisai

Teva

Novartis

Merck

Mylan

Roche

Tesaro

Qilu Pharma

Mundipharma

Heron Therapeutics

Chemotherapy-induced Nausea and Vomiting Drugs Segment by Type

5-HT3 Inhibitors

NK1 Inhibitors

Other

Chemotherapy-induced Nausea and Vomiting Drugs Segment by Application

Moderately Emetogenic Chemotherapy

Highly Emetogenic Chemotherapy

Low Emetogenic Chemotherapy

Other

Chemotherapy-induced Nausea and Vomiting Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Chemotherapy-induced Nausea and Vomiting Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Chemotherapy-induced Nausea and Vomiting Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Chemotherapy-induced Nausea and Vomiting Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Chemotherapy-induced Nausea and Vomiting Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Chemotherapy-induced Nausea and Vomiting Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Chemotherapy-induced Nausea and Vomiting Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Chemotherapy-induced Nausea and Vomiting Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Chemotherapy-induced Nausea and Vomiting Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Chemotherapy-induced Nausea and Vomiting Drugs industry.

Chapter 3: Detailed analysis of Chemotherapy-induced Nausea and Vomiting Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Chemotherapy-induced Nausea and Vomiting Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Chemotherapy-induced Nausea and Vomiting Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Chemotherapy-induced Nausea and Vomiting Drugs Industry Trends Table 2. Chemotherapy-induced Nausea and Vomiting Drugs Industry Drivers Table 3. Chemotherapy-induced Nausea and Vomiting Drugs Industry Opportunities and Challenges Table 4. Chemotherapy-induced Nausea and Vomiting Drugs Industry Restraints Table 5. Global Chemotherapy-induced Nausea and Vomiting Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Chemotherapy-induced Nausea and Vomiting Drugs Revenue Share by Company (2021-2026) Table 7. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Volume by Company (k units) & (2021-2026) Table 8. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Volume Share by Company (2021-2026) Table 9. Global Chemotherapy-induced Nausea and Vomiting Drugs Average Price (US$/unit) of Company (2021-2026) Table 10. Global Chemotherapy-induced Nausea and Vomiting Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global Chemotherapy-induced Nausea and Vomiting Drugs Key Company Manufacturing Base & Headquarters Table 12. Global Chemotherapy-induced Nausea and Vomiting Drugs Company, Product Type & Application Table 13. Global Chemotherapy-induced Nausea and Vomiting Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Chemotherapy-induced Nausea and Vomiting Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of 5-HT3 Inhibitors Table 18. Significant Companies of NK1 Inhibitors Table 19. Significant Companies of Other Table 20. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 21. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Volume by Type (2021-2026) & (k units) Table 22. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Volume by Type (2027-2032) & (k units) Table 23. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Volume Share by Type (2021-2026) Table 24. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Volume Share by Type (2027-2032) Table 25. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Type (2021-2026) Table 29. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Moderately Emetogenic Chemotherapy Table 31. Significant Companies of Highly Emetogenic Chemotherapy Table 32. Significant Companies of Low Emetogenic Chemotherapy Table 33. Significant Companies of Other Table 34. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 35. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Volume by Application (2021-2026) & (k units) Table 36. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Volume by Application (2027-2032) & (k units) Table 37. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Volume Share by Application (2021-2026) Table 38. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Volume Share by Application (2027-2032) Table 39. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Application (2021-2026) Table 43. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Application (2027-2032) Table 44. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 45. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales by Region (2021-2026) & (k units) Table 46. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Market Share by Region (2021-2026) Table 47. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales by Region (2027-2032) & (k units) Table 48. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Market Share by Region (2027-2032) Table 49. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Region (2021-2026) Table 52. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Region (2027-2032) Table 54. Global Chemotherapy-induced Nausea and Vomiting Drugs Market Average Price (US$/unit) by Region (2021-2026) Table 55. Global Chemotherapy-induced Nausea and Vomiting Drugs Market Average Price (US$/unit) by Region (2027-2032) Table 56. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 57. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales by Country (2021-2026) & (k units) Table 59. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Market Share by Country (2021-2026) Table 60. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales by Country (2027-2032) & (k units) Table 61. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Market Share by Country (2027-2032) Table 62. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Market Share by Country (2021-2026) Table 64. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Market Share by Country (2027-2032) Table 66. Eisai Company Information Table 67. Eisai Business Overview Table 68. Eisai Chemotherapy-induced Nausea and Vomiting Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 69. Eisai Chemotherapy-induced Nausea and Vomiting Drugs Product Portfolio Table 70. Eisai Recent Development Table 71. Teva Company Information Table 72. Teva Business Overview Table 73. Teva Chemotherapy-induced Nausea and Vomiting Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 74. Teva Chemotherapy-induced Nausea and Vomiting Drugs Product Portfolio Table 75. Teva Recent Development Table 76. Novartis Company Information Table 77. Novartis Business Overview Table 78. Novartis Chemotherapy-induced Nausea and Vomiting Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 79. Novartis Chemotherapy-induced Nausea and Vomiting Drugs Product Portfolio Table 80. Novartis Recent Development Table 81. Merck Company Information Table 82. Merck Business Overview Table 83. Merck Chemotherapy-induced Nausea and Vomiting Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 84. Merck Chemotherapy-induced Nausea and Vomiting Drugs Product Portfolio Table 85. Merck Recent Development Table 86. Mylan Company Information Table 87. Mylan Business Overview Table 88. Mylan Chemotherapy-induced Nausea and Vomiting Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 89. Mylan Chemotherapy-induced Nausea and Vomiting Drugs Product Portfolio Table 90. Mylan Recent Development Table 91. Roche Company Information Table 92. Roche Business Overview Table 93. Roche Chemotherapy-induced Nausea and Vomiting Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 94. Roche Chemotherapy-induced Nausea and Vomiting Drugs Product Portfolio Table 95. Roche Recent Development Table 96. Tesaro Company Information Table 97. Tesaro Business Overview Table 98. Tesaro Chemotherapy-induced Nausea and Vomiting Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 99. Tesaro Chemotherapy-induced Nausea and Vomiting Drugs Product Portfolio Table 100. Tesaro Recent Development Table 101. Qilu Pharma Company Information Table 102. Qilu Pharma Business Overview Table 103. Qilu Pharma Chemotherapy-induced Nausea and Vomiting Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 104. Qilu Pharma Chemotherapy-induced Nausea and Vomiting Drugs Product Portfolio Table 105. Qilu Pharma Recent Development Table 106. Mundipharma Company Information Table 107. Mundipharma Business Overview Table 108. Mundipharma Chemotherapy-induced Nausea and Vomiting Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 109. Mundipharma Chemotherapy-induced Nausea and Vomiting Drugs Product Portfolio Table 110. Mundipharma Recent Development Table 111. Heron Therapeutics Company Information Table 112. Heron Therapeutics Business Overview Table 113. Heron Therapeutics Chemotherapy-induced Nausea and Vomiting Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 114. Heron Therapeutics Chemotherapy-induced Nausea and Vomiting Drugs Product Portfolio Table 115. Heron Therapeutics Recent Development Table 116. Key Raw Materials Table 117. Raw Materials Key Suppliers Table 118. Chemotherapy-induced Nausea and Vomiting Drugs Distributors List Table 119. Chemotherapy-induced Nausea and Vomiting Drugs Customers List Table 120. Research Programs/Design for This Report Table 121. Authors List of This Report Table 122. Secondary Sources Table 123. Primary Sources List of Figures Figure 1. Chemotherapy-induced Nausea and Vomiting Drugs Product Image Figure 2. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales (2021-2032) & (k units) Figure 5. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Chemotherapy-induced Nausea and Vomiting Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. 5-HT3 Inhibitors Image Figure 10. NK1 Inhibitors Image Figure 11. Other Image Figure 12. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 13. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Volume Share by Type (2021-2032) Figure 15. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Type (2021-2032) Figure 18. Moderately Emetogenic Chemotherapy Image Figure 19. Highly Emetogenic Chemotherapy Image Figure 20. Low Emetogenic Chemotherapy Image Figure 21. Other Image Figure 22. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 23. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Volume Share by Application (2021-2032) Figure 25. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Application (2021-2032) Figure 28. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 29. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America Chemotherapy-induced Nausea and Vomiting Drugs Sales Value (2021-2032) & (US$ Million) Figure 33. North America Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe Chemotherapy-induced Nausea and Vomiting Drugs Sales Value (2021-2032) & (US$ Million) Figure 35. Europe Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific Chemotherapy-induced Nausea and Vomiting Drugs Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America Chemotherapy-induced Nausea and Vomiting Drugs Sales Value (2021-2032) & (US$ Million) Figure 39. South America Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa Chemotherapy-induced Nausea and Vomiting Drugs Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Chemotherapy-induced Nausea and Vomiting Drugs Value Chain Figure 127. Manufacturing Cost Structure Figure 128. Chemotherapy-induced Nausea and Vomiting Drugs Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • 5-HT3 Inhibitors
  • NK1 Inhibitors
  • Other
Applications
  • Moderately Emetogenic Chemotherapy
  • Highly Emetogenic Chemotherapy
  • Low Emetogenic Chemotherapy
  • Other
Companies covered
  • Eisai
  • Teva
  • Novartis
  • Merck
  • Mylan
  • Roche
  • Tesaro
  • Qilu Pharma
  • Mundipharma
  • Heron Therapeutics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Value (2021-2032)
  4. 1.2.2 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Chemotherapy-induced Nausea and Vomiting Drugs Market Dynamics
  1. 2.1 Chemotherapy-induced Nausea and Vomiting Drugs Industry Trends
  2. 2.2 Chemotherapy-induced Nausea and Vomiting Drugs Industry Drivers
  3. 2.3 Chemotherapy-induced Nausea and Vomiting Drugs Industry Opportunities and Challenges
  4. 2.4 Chemotherapy-induced Nausea and Vomiting Drugs Industry Restraints
3 Chemotherapy-induced Nausea and Vomiting Drugs Market by Company
  1. 3.1 Global Chemotherapy-induced Nausea and Vomiting Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Chemotherapy-induced Nausea and Vomiting Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global Chemotherapy-induced Nausea and Vomiting Drugs Average Price by Company (2021-2026)
  5. 3.5 Global Chemotherapy-induced Nausea and Vomiting Drugs Company Ranking (2024-2026)
  6. 3.6 Global Chemotherapy-induced Nausea and Vomiting Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global Chemotherapy-induced Nausea and Vomiting Drugs Company Product Type and Application
  8. 3.8 Global Chemotherapy-induced Nausea and Vomiting Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Chemotherapy-induced Nausea and Vomiting Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Chemotherapy-induced Nausea and Vomiting Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Chemotherapy-induced Nausea and Vomiting Drugs Market by Type
  1. 4.1 Chemotherapy-induced Nausea and Vomiting Drugs Type Introduction
  2. 4.1.1 5-HT3 Inhibitors
  3. 4.1.2 NK1 Inhibitors
  4. 4.1.3 Other
  5. 4.2 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Volume by Type
  6. 4.2.1 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Value by Type
  10. 4.3.1 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Value by Type (2021-2032)
  12. 4.3.3 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Type (2021-2032)
5 Chemotherapy-induced Nausea and Vomiting Drugs Market by Application
  1. 5.1 Chemotherapy-induced Nausea and Vomiting Drugs Application Introduction
  2. 5.1.1 Moderately Emetogenic Chemotherapy
  3. 5.1.2 Highly Emetogenic Chemotherapy
  4. 5.1.3 Low Emetogenic Chemotherapy
  5. 5.1.4 Other
  6. 5.2 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Volume by Application
  7. 5.2.1 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Value by Application
  11. 5.3.1 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Value by Application (2021-2032)
  13. 5.3.3 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Application (2021-2032)
6 Chemotherapy-induced Nausea and Vomiting Drugs Regional Sales and Value Analysis
  1. 6.1 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales by Region (2027-2032)
  5. 6.3 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global Chemotherapy-induced Nausea and Vomiting Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Chemotherapy-induced Nausea and Vomiting Drugs Sales Value (2021-2032)
  12. 6.6.2 North America Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Chemotherapy-induced Nausea and Vomiting Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Chemotherapy-induced Nausea and Vomiting Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Chemotherapy-induced Nausea and Vomiting Drugs Sales Value (2021-2032)
  21. 6.9.2 South America Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Chemotherapy-induced Nausea and Vomiting Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Country, 2025 VS 2032
7 Chemotherapy-induced Nausea and Vomiting Drugs Country-level Sales and Value Analysis
  1. 7.1 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales by Country (2027-2032)
  6. 7.4 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Chemotherapy-induced Nausea and Vomiting Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Eisai
  2. 8.1.1 Eisai Company Information
  3. 8.1.2 Eisai Business Overview
  4. 8.1.3 Eisai Chemotherapy-induced Nausea and Vomiting Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Eisai Chemotherapy-induced Nausea and Vomiting Drugs Product Portfolio
  6. 8.1.5 Eisai Recent Developments
  7. 8.2 Teva
  8. 8.2.1 Teva Company Information
  9. 8.2.2 Teva Business Overview
  10. 8.2.3 Teva Chemotherapy-induced Nausea and Vomiting Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Teva Chemotherapy-induced Nausea and Vomiting Drugs Product Portfolio
  12. 8.2.5 Teva Recent Developments
  13. 8.3 Novartis
  14. 8.3.1 Novartis Company Information
  15. 8.3.2 Novartis Business Overview
  16. 8.3.3 Novartis Chemotherapy-induced Nausea and Vomiting Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Novartis Chemotherapy-induced Nausea and Vomiting Drugs Product Portfolio
  18. 8.3.5 Novartis Recent Developments
  19. 8.4 Merck
  20. 8.4.1 Merck Company Information
  21. 8.4.2 Merck Business Overview
  22. 8.4.3 Merck Chemotherapy-induced Nausea and Vomiting Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Merck Chemotherapy-induced Nausea and Vomiting Drugs Product Portfolio
  24. 8.4.5 Merck Recent Developments
  25. 8.5 Mylan
  26. 8.5.1 Mylan Company Information
  27. 8.5.2 Mylan Business Overview
  28. 8.5.3 Mylan Chemotherapy-induced Nausea and Vomiting Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Mylan Chemotherapy-induced Nausea and Vomiting Drugs Product Portfolio
  30. 8.5.5 Mylan Recent Developments
  31. 8.6 Roche
  32. 8.6.1 Roche Company Information
  33. 8.6.2 Roche Business Overview
  34. 8.6.3 Roche Chemotherapy-induced Nausea and Vomiting Drugs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Roche Chemotherapy-induced Nausea and Vomiting Drugs Product Portfolio
  36. 8.6.5 Roche Recent Developments
  37. 8.7 Tesaro
  38. 8.7.1 Tesaro Company Information
  39. 8.7.2 Tesaro Business Overview
  40. 8.7.3 Tesaro Chemotherapy-induced Nausea and Vomiting Drugs Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Tesaro Chemotherapy-induced Nausea and Vomiting Drugs Product Portfolio
  42. 8.7.5 Tesaro Recent Developments
  43. 8.8 Qilu Pharma
  44. 8.8.1 Qilu Pharma Company Information
  45. 8.8.2 Qilu Pharma Business Overview
  46. 8.8.3 Qilu Pharma Chemotherapy-induced Nausea and Vomiting Drugs Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Qilu Pharma Chemotherapy-induced Nausea and Vomiting Drugs Product Portfolio
  48. 8.8.5 Qilu Pharma Recent Developments
  49. 8.9 Mundipharma
  50. 8.9.1 Mundipharma Company Information
  51. 8.9.2 Mundipharma Business Overview
  52. 8.9.3 Mundipharma Chemotherapy-induced Nausea and Vomiting Drugs Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Mundipharma Chemotherapy-induced Nausea and Vomiting Drugs Product Portfolio
  54. 8.9.5 Mundipharma Recent Developments
  55. 8.10 Heron Therapeutics
  56. 8.10.1 Heron Therapeutics Company Information
  57. 8.10.2 Heron Therapeutics Business Overview
  58. 8.10.3 Heron Therapeutics Chemotherapy-induced Nausea and Vomiting Drugs Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Heron Therapeutics Chemotherapy-induced Nausea and Vomiting Drugs Product Portfolio
  60. 8.10.5 Heron Therapeutics Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Chemotherapy-induced Nausea and Vomiting Drugs Value Chain Analysis
  2. 9.1.1 Chemotherapy-induced Nausea and Vomiting Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Chemotherapy-induced Nausea and Vomiting Drugs Sales Mode & Process
  6. 9.2 Chemotherapy-induced Nausea and Vomiting Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Chemotherapy-induced Nausea and Vomiting Drugs Distributors
  9. 9.2.3 Chemotherapy-induced Nausea and Vomiting Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst